SmallCaps
ASX:LDXHealth Care Equipment & ServicesHealth Care Supplies

Lumos Diagnostics Holdings Ltd

$0.100
Day Range
$0.100 – $0.110
52 Week Range
$0.072 – $0.330
Volume
0.00
Avg Volume (10D)
3.58M
Market Cap
$94.48M
Price Chart
Market Statistics
Open$0.100
Previous Close$0.100
Day High$0.110
Day Low$0.100
52 Week High$0.330
52 Week Low$0.072
Valuation
Market Cap94.48M
Shares Outstanding944.82M
Price to Book10.57
Trading Activity
Volume0.00
Value Traded0.00
Bid$0.105 × 45
Ask$0.105 × 109,203
Performance
1 Day-9.09%
5 Day-9.09%
13 Week-41.18%
52 Week36.99%
YTD-64.91%
Technical Indicators
RSI (14)48.94
50-Day SMA$0.105
200-Day SMA$0.197
Latest News
Lumos Diagnostics Expands FebriDx Rollout Across Priority US Urgent Care Accounts
Biotechnology

Lumos Diagnostics Expands FebriDx Rollout Across Priority US Urgent Care Accounts

Lumos Diagnostics expands FebriDx rollout to 430 US urgent care sites across top accounts, targeting 2.6 million ARI visits annually—rapid expansion under way.

By Nik Hill··2 min read min read
Lumos Diagnostics Achieves BARDA Paediatric Study Milestone, Secures US$720k Payment
Biotechnology

Lumos Diagnostics Achieves BARDA Paediatric Study Milestone, Secures US$720k Payment

Lumos Diagnostics hits BARDA Milestone 6, secures US$720k non-dilutive payment as FebriDx paediatric study advances toward FDA submission and wider US TAM.

By Isla Campbell··2 min read min read
Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test
Biotechnology

Lumos Diagnostics Secures Full US Medicare Reimbursement Recognition for FebriDx Test

Lumos Diagnostics (ASX: LDX) has achieved complete US Medicare reimbursement recognition for its FebriDx point-of-care diagnostic test, securing coverage from all seven Medicare Administrative Contractors.

By Nik Hill··1 min read min read
Lumos Diagnostics secures US government funding to develop groundbreaking FebriDx test
Biotechnology

Lumos Diagnostics secures US government funding to develop groundbreaking FebriDx test

Lumos Diagnostics (ASX: LDX) has received significant US financial backing for its development of unique point-of-care diagnostic test technology. Lumos has been awarded approximately $4.3 million by a division of the US government’s health division to support a planned study and regulatory submission for the company’s FebriDx bacterial/non-bacterial test. FebriDx is designed to assess whether […]

By Colin Hay··1 min read min read